openPR Logo
Press release

A Billion dollar boom in RNA Based Therapeutics Market to reach $1.2 billion by 2020, registering a CAGR of 28.4%.

04-18-2019 04:10 PM CET | Health & Medicine

Press release from: Allied Market Research

A Billion dollar boom in RNA Based Therapeutics Market to reach

RNA Based Therapeutics Market is expected to garner $1.2 billion by 2020, registering a CAGR of 28.4% during the forecast period 2014 - 2020. The Global RNA based therapeutics Market has garnered significant attention in recent years due to its potential to treat a variety of chronic diseases such as cancer, diabetes, AIDS, Tuberculosis and certain cardiovascular conditions.

Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/546?utm_source=openpr&utm_medium=Niranjan

Despite being in the clinical research phase, the RNA based therapeutics is been explored as a promising treatment option for the diseases which are difficult to treat. Development of this therapeutics is based on promising technologies such as RNA interference technology (RNAi), antisense technology and SMaRT technology. RNAi technology and antisense technology together are gaining prominence in the research industry, as these technologies provide base sequence to develop RNA drugs. RNAi technology works by causing destruction of specific mRNA molecules; whereas, antisense technology works by synthesizing a strand of RNA from the known gene sequence.

These newly synthesized RNA strands then itself binds to mRNA and make mRNA inactive. Gene silencing potential of RNA based therapeutics is the primary driver for the growth of this market. The other drivers include target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. However, critical issues in drug delivery, high cost of research, and high failure rates are some of the major hurdles for the companies working in this field.

Despite the restraints, RNA based therapeutics has the potential to grow due to increasing interest exhibited by the pharmaceutical industries for the commercialization of these therapies. Quark Pharmaceuticals, Inc. (USA), Alnylam Pharmaceuticals, Inc. (the USA), Dicerna Pharmaceuticals, Inc. (the USA), Tekmira Pharmaceuticals Corp. (Canada), Benitec Biopharma Limited (Australia), Genzyme Corporation (USA), ISIS Pharmaceuticals Inc (USA), Silence Therapeutics PLC (UK) and Cenix BioScience GmbH (Germany) are some of the key players in this market. ISIS Pharmaceuticals, Inc. (USA) has focused its research activities on antisense technology and developed antisense therapeutics, namely Mipomersen and Fomivirsen. This therapeutics is commercially available in the market and marketed as Kynamro and Vitravene respectively. Quark, Alnylam and silence therapeutics are other major players of this market with strong research pipeline in RNA based therapeutics.

Purchase Inquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/546?utm_source=openpr&utm_medium=Niranjan

RNA based therapeutics market is segmented into technology, application, end-users, and geography. The technology segment is further categorized as enabling technologies and enabled technologies. The segment of enabling technologies comprises of Microarrays, Labeling, Purification, Linear amplification, qRT-PCR, and Inhibition; whereas, enabled technologies to include RNA interference technology (RNAi) and RNA antisense technology. Enabled technologies account for the largest market share due to their potential use in therapeutics. The market for RNA based therapeutics is dominated by RNA interference technology as numerous companies have exhibited their interest to develop RNA drugs using RNAi technology.

RNA based therapeutics have wide applications covering a variety of chronic conditions such as Cardiovascular, Kidney Diseases, Oncology, Infectious diseases, Metabolic disorders, and Others. The pipeline research is concentrated towards oncology and infectious diseases due to their high prevalence and failure of existing treatment to effectively treat these conditions. The end user market is segmented into research, therapeutics, and diagnostics. Currently, research and diagnostics segments are largely exploring the RNA technologies and therapies for the commercialization of RNA drugs.

Geographically, RNA based therapeutics market is segmented into North America, Europe, Asia-Pacific, and LAMEA. Potential regions of the respective geographies are strategically analyzed to provide country wise focus on RNA research activities. North America dominates the RNA based therapeutics followed by Europe and Asia-Pacific. The key market players belong to North America and are conducting extensive research to commercialize the therapeutics. Moreover, the growth in North America and Europe is primarily driven by substantial investment in research, advancement in RNA platform technologies, government support and availability of suitable infrastructure to develop the novel RNA based therapies. However, business dynamics in Asia-pacific is anticipated to offer tremendous opportunities to major players of this market as the cost of clinical research is less in this region as compared to North America and Europe.

KEY BENEFITS:

An in-depth analysis of research and clinical developments within RNA based therapeutics market is provided and light is shed on market dynamics that would prove crucial in understanding the market.
Quantitative analysis of the current market and estimations through 2013-2020 would assist strategists to design business strategies to capitalize on the prevailing opportunities in the market.
Competitive structure of RNA based therapeutics market is analyzed through Porters Five Forces model and provides an in-depth understanding of the influencing factors for commercialization of RNA therapeutics.
The detailed study of the strategies of key leaders, partnerships, acquisitions and clinical trials in the RNA based therapeutics market would be informative for professionals in the corporate sector.
Pin-point analysis of geographic segments would assist in the identification of most profitable segments to capitalize on.

KEY MARKET SEGMENTS

RNA based therapeutics market is segmented into four major categories such as Technology, Application, End Users and Geography.

MARKET BY TECHNOLOGY:
Enabling technologies
Microarrays
Labeling
Purification
Linear amplification
qRT-PCR
Inhibition
Enabled technologies
RNA Interference (RNAi) technologies
Small interfering RNA (siRNA)
MicroRNA (miRNA)
RNA antisense technologies

MARKET BY APPLICATION:
Cardiovascular
Kidney Diseases
Oncology
Infectious diseases
Metabolic disorders
Others

MARKET BY END USERS:
Research
Therapeutics
Diagnosis

MARKET BY GEOGRAPHY:
North America
The U.S.
Canada
Europe
Germany
The U.K.
France
Others
Asia Pacific
LAMEA

About Us:-

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact Us:-

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release A Billion dollar boom in RNA Based Therapeutics Market to reach $1.2 billion by 2020, registering a CAGR of 28.4%. here

News-ID: 1709771 • Views:

More Releases from Allied Market Research

Spa Services Market Poised for Substantial growth, Reaching $423.25 Billion by 2031 at 17.3% CAGR
Spa Services Market Poised for Substantial growth, Reaching $423.25 Billion by 2 …
Allied Market Research published a new report, titled, "Spa Services Market by Type and Geography - Global Opportunity Analysis and Industry Forecast, 2022-2031". The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends. Download Exclusive PDF Sample Report @https://www.alliedmarketresearch.com/request-sample/1502 Growth of the market is fostered by factors such as increased hectic lifestyles, rise in wellness
SOC as a Service Market Share Reach USD 9.9 Billion by 2031
SOC as a Service Market Share Reach USD 9.9 Billion by 2031
Allied Market Research published a new report, titled, " The SOC as a Service Market Share Reach USD 9.9 Billion by 2031." The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter's Five Forces analysis, and competitive landscape. This study is a helpful source of information for market players, investors, VPs, stakeholders, and new entrants to gain thorough understanding of the industry and determine steps
A Look at the Microbial Incubators Market | Is Projected to Reach $508.5 Million By 2032
A Look at the Microbial Incubators Market | Is Projected to Reach $508.5 Million …
Microbial incubators, those unsung heroes of countless laboratories, are the controlled environments where the tiny powerhouses of life - microbes - flourish. From culturing bacteria for medical research to fostering yeast strains for beer production, these incubators are vital tools across various scientific disciplines. The global microbial incubators market size was valued at $315.2 million in 2022, and is projected to reach $508.5 million by 2032, growing at a CAGR
Market Growth of Automotive RADAR Industry : $4.08 Billion in 2020, Projected to Reach $10.06 Billion by 2028, CAGR of 12.6% (2021-2028)
Market Growth of Automotive RADAR Industry : $4.08 Billion in 2020, Projected to …
According to a recent report published by Allied Market Research, titled, "Automotive RADAR Market Size, Share, Competitive Landscape and Trend Analysis Report by Application, Frequency, Range and Vehicle Type Global Opportunity Analysis and Industry Forecast, 2021-2028". 𝐀𝐮𝐭𝐨𝐦𝐨𝐭𝐢𝐯𝐞 𝐑𝐀𝐃𝐀𝐑 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐭𝐚𝐭𝐢𝐬𝐭𝐢𝐜𝐬 𝟐𝟎𝟐𝟏-𝟐𝟎𝟐𝟖 : The global automotive RADAR market was valued at $4.08 billion in 2020, and is projected to reach $10.06 billion by 2028, registering a CAGR of 12.6%. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬

All 5 Releases


More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and